Biopharmx (NYSEAMERICAN:BPMX) released its earnings results on Thursday. The biotechnology company reported ($0.02) EPS for the quarter, hitting analysts’ consensus estimates of ($0.02), Bloomberg Earnings reports.

Shares of BPMX opened at $0.16 on Friday. Biopharmx has a 12-month low of $0.10 and a 12-month high of $0.39.

Separately, Maxim Group reaffirmed a “buy” rating and set a $1.50 price objective on shares of Biopharmx in a research note on Friday, June 8th.

About Biopharmx

BioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter (OTC) products that address dermatology and women's health markets. The company offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort, as well as alleviates the symptoms of fibrocystic breast condition (FBC).

Read More: Market Capitalization

Earnings History for Biopharmx (NYSEAMERICAN:BPMX)

Receive News & Ratings for Biopharmx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx and related companies with's FREE daily email newsletter.